| Company/Division name | Raybow Pharmaceutical |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 74 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2026 |
| Capital investment ($): | 15.8 |
| Country(ies) from which reshored: | China |
| City reshored to: | Brevard |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | active pharmaceutical ingredient manufacturing |
| What domestic positive factors made reshoring more attractive? | Under-utilized capacity |
